Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test

News   Jan 25, 2013

 
Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test
 
 

RELATED ARTICLES

Acquisition Sees Agilent Gain Powerful NGS IP Portfolio

News

Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.

READ MORE

Potential Barcode Identified for a Form of Alcoholic Liver Disease

News

NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.

READ MORE

Optofluidic Device Detects Tumour Cells in Blood

News

A team of researchers has patented a mobile device that can monitor cancer quickly, cheaply, effectively and non-invasively.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE